The Globe and Mail reports in its Friday, Feb. 9, edition that RBC Capital analyst Douglas Miehm has reaffirmed his "outperform" recommendation for Bausch + Lomb. The Globe's David Leeder writes in the Eye On Equities column that Mr. Miehm gave his share target a $1 trim to $19 (all figures U.S.). Analysts on average target the shares at $19.55. Bausch + Lomb releases quarterly results on Feb. 21. Mr. Miehm says in a note: "We estimate Q4/23 revenue of $1,159-million (cons. $1,105-million) and adj. EBITDA of $224-million (cons. $228-million)," he said. "Q4/23 will continue to be influenced by FX headwinds ($6-million RBC estimate vs. management guidance of $26-million). We expect the focus to be on 2024 guidance and outlook for Xiidra and Miebo. We have incorporated updated FX, updated our outlook for Miebo and Xiidra utilizing the latest Rx data and have increased investment spending to support the new launches." The Globe reported on July 27, 2022, Feb. 16, 2023, and Oct. 4, 2023, that Mr. Miehm rated Bausch + Lomb "outperform." The shares could then be had for $14.50, $19 and $16.17. The Globe reported on Nov. 29, 2023, that Barclays warned that Bausch + Lomb was facing stiff headwinds when it was worth $15.24.